Decoding Neurological Disease. Building Medicines.

CMT1A and related neurological disorders still have no approved disease-modifying therapies. We are changing that — by integrating deep disease biology, bioprinted neuro-mimetic models, and multiscale AI into a unified drug discovery platform.

A New Paradigm in Neurotherapeutics
We are building a new approach to neurological drug discovery — one that integrates real disease biology and AI to predict, from the outset, which molecules will work in patients.

Targeting CMT1A Root Cause
We are advancing a robust pipeline of precision therapies for CMT1A — the most common inherited peripheral neuropathy. Our therapeutics are designed to reverse the core disease pathology and restore peripheral nerve function.

Where Biology Meets AI
Our PRECISION™ platform captures high-content phenotypic data across 20,000+ compounds using proprietary 3D neuro-mimetic models. This 20TB+ biological dataset powers our AI to generate predictive drug candidate signatures.

Partner With Us
We are building strategic alliances to accelerate our CMT1A programs and expand the reach of our PRECISION™ AI platform.

Join the Team
Build the future of precision medicine at the intersection of neuroscience and AI.

A New Paradigm in Neurotherapeutics We are building a new approach to neurological drug discovery — one that integrates real disease biology and AI to predict, from the outset, which molecules will work in patients.

Targeting CMT1A Root Cause We are advancing a robust pipeline of precision therapies for CMT1A — the most common inherited peripheral neuropathy. Our therapeutics are designed to reverse the core disease pathology and restore peripheral nerve function.

Where Biology Meets AI Our PRECISION™ platform captures high-content phenotypic data across 20,000+ compounds using proprietary 3D neuro-mimetic models. This 20TB+ biological dataset powers our AI to generate predictive drug candidate signatures.

A New Paradigm in Neurotherapeutics
We are building a new approach to neurological drug discovery — one that integrates real disease biology and AI to predict, from the outset, which molecules will work in patients.

Targeting CMT1A Root Cause
We are advancing a robust pipeline of precision therapies for CMT1A — the most common inherited peripheral neuropathy. Our therapeutics are designed to reverse the core disease pathology and restore peripheral nerve function.

Where Biology Meets AI
Our PRECISION™ platform captures high-content phenotypic data across 20,000+ compounds using proprietary 3D neuro-mimetic models. This 20TB+ biological dataset powers our AI to generate predictive drug candidate signatures.